Anti-Human CD45 (PTPRC) Clone (CPTC-PTPRC-1) – Purified No Carrier Protein

PTPRC synthetic ligand LFLAEFQSIPR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FHC-104A-13-7 activity is directed against human CD45 (PTPRC) peptide sequence LFLAEFQSIPR.

CPTC-PTPRC-1

Protein tyrosine phosphatase receptor type C (PTPRC or CD45) is a type I transmembrane glycoprotein that is an essential regulator of T and B lymphocyte activation, development, tolerance, and survival, as well as plays an essential role in the innate immune system¹. PTPRC regulates the interaction between T cells and macrophages and additionally acts as a negative regulator of monocytic cell differentiation. Furthermore, PTPRC plays roles in chromatin condensation and DNA fragmentation as well as acts as a negative regulator of JAK/STAT signaling. PTPRC also controls immune function by regulating cytokine responses, lymphocyte survival, and TCR signaling.

Alternative splicing of PTPRC leads to different isoform options with varying O-linked glycosylation being expressed by different lineages and differentiation stages of hematopoietic stem cells (HSC)¹. These different isoforms play roles in HSC proliferation and differentiation and can also be used as biomarkers to distinguish between the different types of immune cells expressing them.

Dysregulation of PTPRC can lead to autoimmune infectious diseases, severe combined immunodeficiency, acute myeloid leukemia, lymphoma, multiple sclerosis, ectopic bone formation, and defective cellular motility¹. Consequently, PTPRC is a therapeutic target for immune diseases and organ transplantation.

FHC-104A-13-7 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from human PTPRC, LFLAEFQSIPR². FHC-104A-13-7 does not detect PTPRC by immunohistochemistry or reverse phase protein array³.

CD45 (PTPRC) is expressed on the cell surface of almost all hematopoietic stem cells, except erythrocytes and platelets.

PUL11, PP14, lectins, DPP4, SKAP1, CD53

1 Al Barashdi MA, Ali A, McMullin MF, et al. J Clin Pathol. 74(9):548-552. 2021.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/ProteinTyrosinePhosphataseReceptorTypeCPeptide1